Dry mouth – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Mon, 03 Aug 2026 10:38:56 +0000 en-US hourly 1 https://wordpress.org/?v=7.1 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Dry mouth – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of ADRC001 (Adipose-Derived Stem Cells) for treating dry mouth (xerostomia) in patients who received radiation therapy for head and neck cancer https://clinicaltrials.eu/trial/study-of-adrc001-adipose-derived-stem-cells-treatment-for-dry-mouth-in-head-and-neck-cancer-survivors-who-received-radiation-therapy/ Mon, 03 Aug 2026 10:38:56 +0000 https://clinicaltrials.eu/trial/study-of-adrc001-adipose-derived-stem-cells-treatment-for-dry-mouth-in-head-and-neck-cancer-survivors-who-received-radiation-therapy/ This study focuses on treating xerostomia (dry mouth) that occurs after radiation therapy in people who have survived head and neck cancer. This condition develops when radiation treatment damages the salivary glands, leading to reduced saliva production and persistent mouth dryness. The study aims to determine if injecting specially processed stem cells called Adipose Derived Regenerative Cells (ADRC001) into the salivary glands can improve saliva production.

The treatment involves receiving two injections of either ADRC001 or sterile isotone saline (placebo) directly into the salivary glands. These stem cells are derived from fat tissue and are processed in a laboratory to create a specialized cell therapy product. The treatment will be administered over a period of several months to evaluate its effectiveness in improving saliva production.

The study will monitor participants for 8 months to measure changes in their saliva production. The cell therapy being tested represents an innovative approach to treating radiation-induced dry mouth, which can significantly impact quality of life for cancer survivors. This research explores whether these stem cell injections can help restore the natural function of salivary glands that have been damaged by radiation therapy.

]]> Study on Pilocarpine Hydrochloride for Dry Mouth in Adults with Life-Limiting Conditions or Frailty https://clinicaltrials.eu/trial/study-on-pilocarpine-hydrochloride-for-dry-mouth-in-adults-with-life-limiting-conditions-or-frailty/ Mon, 03 Aug 2026 10:14:57 +0000 https://clinicaltrials.eu/trial/study-on-pilocarpine-hydrochloride-for-dry-mouth-in-adults-with-life-limiting-conditions-or-frailty/ This clinical trial is focused on studying xerostomia, commonly known as dry mouth, in adults who have a life-limiting condition or are experiencing frailty. The treatment being tested is pilocarpine hydrochloride, which is administered as oral drops. The purpose of the study is to evaluate how effective these drops are in reducing the discomfort of dry mouth compared to a placebo.

Participants in the study will receive the treatment of pilocarpine hydrochloride three times a day for a period of four weeks. The study aims to observe any changes in the severity of dry mouth symptoms and to assess the overall impact on the participants’ quality of life. The study will also monitor any side effects that may occur from using pilocarpine hydrochloride.

The trial will measure the effectiveness of the treatment by looking at the reduction in dry mouth symptoms and improvements in oral health-related quality of life. Participants’ feedback on the treatment’s applicability and any potential side effects will also be collected. The study will continue to follow participants for up to 12 weeks to evaluate the long-term effects of the treatment.

]]>